Search clinical trials for: BI 201335 (Test)

Total 10812 results

Boehringer Ingelheim

Completed

A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment (PARTRIDGE)

Diabetic Retinopathy

Spain, United Kingdom, United States, Netherlands, Australia, Latvia
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated

Healthy

Japan
Alkahest, Inc.

Completed

Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration

Wet Age-related Macular Degeneration

Hungary
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 14332 CL Powder in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

BI 2536 BS in Patients With Advanced Solid Tumours and Repeated Administration in Patients With Clinical Benefit

Neoplasms
Boehringer Ingelheim

Terminated

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 14332 CL as Tablet in Female and Male Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 730357 is Processed by the Body

Healthy

Netherlands
Scleroderma Research Foundation, Inc.
Sanofi; Boehringer Ingelheim

Not yet recruiting

Platform Clinical Study for Conquering Scleroderma (CONQUEST)

Scleroderma | Interstitial Lung Disease Due to Systemic Disease

United States
University of Michigan Rogel Cancer Center

Not yet recruiting

Feasibility of Expressive Writing for Body Image Distress and Anxiety Among Adolescent and Young Adult Cancer Survivors

Body Image | Adolescent Cancer | Young Adult Cancer

United States
Boehringer Ingelheim

Active, not recruiting

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

Lung Diseases, Interstitial

United States, Spain, China, United Kingdom, Canada, Norway, Korea, Republic of, Belgium, Australia, Germany, Denmark, Singapore, Taiwan, Thailand, Italy, Japan, Finland, Turkey, Croatia, Switzerland, France, Serbia, Netherlands, Mala... and more
Boehringer Ingelheim

Active, not recruiting

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight (SYNCHRONIZE™-1)

Obesity

United States, Korea, Republic of, Belgium, Australia, China, Poland, Japan, Finland, Germany, Canada, Netherlands, New Zealand, Sweden, United Kingdom
Boehringer Ingelheim

Active, not recruiting

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

United States, Spain, China, Canada, Norway, Korea, Republic of, Taiwan, Belgium, Australia, Germany, Denmark, Singapore, Thailand, Italy, Japan, United Kingdom, Switzerland, Croatia, France, Netherlands, Malaysia, New Zealand, Arge... and more
Boehringer Ingelheim

Completed

Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655130 in Healthy Male Volunteers

Healthy

Belgium
Boehringer Ingelheim

Completed

Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655130 in Healthy Male Volunteers

Healthy

Belgium
Boehringer Ingelheim

Completed

Single Rising Dose Trial of Spesolimab (BI 655130) for Healthy Japanese Male Subjects

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

A Study in Healthy Men to Find Out How BI 1015550 is Taken up and Handled by the Body

Healthy

Netherlands
Alkahest, Inc.

Completed

Evaluate the Effects and Safety of ALK4290 in Patients With Newly Diagnosed Wet Age-Related Macular Degeneration

Wet Age-related Macular Degeneration

Hungary
Boehringer Ingelheim

Completed

Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer

Neoplasms

United States, Taiwan
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 11054 CL Administered With the Respimat® in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 44370 TA Tablets in Healthy Male and Female Volunteers

Healthy
Duke University

Completed

Early Detection of Lung Cancer Via Bi-plane Correlation Chest Imaging

Lung Cancer | Metastatic Cancer in the Lungs

United States
Boehringer Ingelheim

Completed

Utilization of HIV Drug Resistance Testing in Treatment Experienced Patients (UTILIZE Study)

HIV Infections

United States, Puerto Rico
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Different Doses of BI 1815368 Are Tolerated and How BI 1815368 is Taken up in the Body With or Without Food

Healthy

Germany
Boehringer Ingelheim

Completed

Metabolism and Pharmacokinetics of [14C]-BI 409306 After Administration as Oral Solution in Healthy Male Volunteers

Healthy

United Kingdom
Boehringer Ingelheim

Recruiting

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

Obesity

United States, Korea, Republic of, Belgium, Australia, United Kingdom, Mexico, Spain, Germany, Taiwan, Netherlands, Brazil, Hungary, Denmark, Canada, Poland, Austria, China, Finland, Greece, Italy, Hong Kong, Czechia, Portugal, Saudi... and more
Assiut University
WGEKHALEEL; AARMHUSSIEN

Recruiting

HFNC in Management of Bronchiectasis Exacerbation

Bronchiectasis

Egypt
Boehringer Ingelheim

Recruiting

A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms (VITALISScE™)

Scleroderma, Systemic

United States, Belgium, Korea, Republic of, Australia, China, Taiwan, Spain, Israel, Japan, Mexico, Turkey, Germany, Italy, Brazil, France, Singapore, Canada, Philippines, United Kingdom, Switzerland, Finland, Greece, New Zealand, Den... and more
Boehringer Ingelheim

Recruiting

A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma

Glioblastoma

Belgium, Spain, United States
Universitat Jaume I

Not yet recruiting

Blended Treatment for Problem Gambling and Gambling Disorder Combining Group Sessions and Online Modules

Gambling Disorder | Problem Gambling

Spain
Boehringer Ingelheim

Completed

A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight

Obesity

Belgium, Australia, Sweden, United States, Canada, Germany, Korea, Republic of, China, Netherlands, New Zealand, United Kingdom, Poland
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 456906 is Processed in the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients

Multiple Myeloma

Germany, France
Boehringer Ingelheim

Completed

Relative Bioavailability of a Single Dose of BI 44370 Tablet During and Between Migraine Attacks

Migraine Disorders

Belgium, Germany
Stereotaxis

Terminated

MAGNET CRT Feasibility - Efficiency of LV Lead Placement Comparing Conventional vs. Magnetic Guidance

Cardiac Resynchronization Therapy

United States
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Mono Products of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Free Combination of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers

Healthy
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé Et de la Recherche Médicale, France; Institut... and other collaborators

Completed

Ontogeny of MAIT Cells in Neonates and Hematopoietic Stem Cell Transplant Recipients (NEOMAIT)

Term and Preterm Neonates (24-41 Weeks Gestational Age) | Hematopoietic Stem Cell Transplant Recipient Children

France
Hacettepe University
Suleyman Demirel University

Completed

Postural and Anthropometric Properties of Foot and Ankle of Patients With DMD

Duchenne Muscular Dystrophy | Ambulation Difficulty | Posture Disorders in Children | Ambulation Disorder, Neurologic

Turkey
Postgraduate Institute of Medical Education and...

Recruiting

Global Coagulation Assessment in Portal Vein Thrombosis and Budd-Chiari Syndrome (Liv-Thrombus)

Portal Vein Thrombosis | Anticoagulants and Bleeding Disorders | Hepatic Vein Thromboses | Hepatic Venous Outflow Obstruction | Portal Hypertension, Noncirrhotic | Portal Vein Occlusion | Portal Vein Embolism | JAK2 Mutation | CALR Gene Mutation | Prothrombin G20210A

India
Boehringer Ingelheim

Completed

To Investigate the Safety, Tolerability, Pharmacokinetics and the Relative Bioavailability of BI 1026706

Healthy

Germany
Oklahoma State University

Recruiting

Exercise-Induced Gut Permeability in Normal-weight Obesity

Obesity | Normal-weight Obesity

United States
Boehringer Ingelheim

Completed

4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer

Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditions

United States
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 207127 NA in Healthy Male Asian Volunteers and Single Dose Study of BI 207127 NA in Healthy Male Caucasian Volunteers

Healthy

Korea, Republic of
Boehringer Ingelheim

Terminated

A Study in Healthy Men to Test How BI 1265162 is Taken up and Processed by the Body

Healthy Volunteers

Netherlands
University Hospital, Brest

Terminated

Validation of a Walk-Time Limit Test (WTLT) Derived From the 6-Minute Walk Test (6-MWT) in Patients With Chronic Cardiovascular or Respiratory Diseases (TTLM)

Chronic Obstructive Pulmonary Disease | Cardiovascular Insufficiency

France
Boehringer Ingelheim
Eli Lilly and Company

Completed

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

Diabetes Mellitus, Type 2

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Croatia, Czech Republic, Denmark, Estonia, France, Georgia, Greece, Hong Kong, Hungary, India, Indonesia, Israel, Italy, Japan, Korea, Republic of, Malaysia and more
Boehringer Ingelheim

Completed

Effect of Food on the Pharmacokinetics of BI 1060469 (Formulation Tablet) in Healthy Male Subjects

Healthy

Germany
Organogenesis

Terminated

Apligraf Versus Standard Therapy in the Treatment of Diabetic Foot Ulcers

Diabetic Foot
Rennes University Hospital

Completed

Estimation of Myocardial Iron Overload by 3 Tesla MRI in HFE Hereditary Haemochromatosis (HEMOCOEUR)

Myocardial Iron Overload | HFE-Associated Hereditary Hemochromatosis

France

Search clinical trials for: BI 201335 (Test)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Greece

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations